Mexichem Fluor is active in assisting pharmaceutical companies around the world to make the transition from CFC propellants, traditionally used in metered dose inhalers (MDIs), to long-term products such as hydrofluoroalkanes (HFAs).
Our expertise enables us to help companies make the transition away from CFCs as quickly and as 'seamlessly' as possible, conscious that the needs of the patient are paramount.
While our business is the leading producer and supplier of HFA medical propellants and associated services − see the ZEPHEX® range − we recognise that there are still a small number of "essential use" applications where CFC propellants are still required to ensure ongoing patient care in the developing world.
Since 1st January 2010 any remaining CFCs that are required in the developing world, to provide 'bridging' to the new HFA propelled products, may have to come from a different source than used previously. Whilst we can no longer supply CFCs we are prepared to provide our expertise and advice in helping pharmaceutical companies ensure that any CFCs used by them are safe and fit for purpose.